QVAR 40 Drug Patent Profile

Which patents cover Qvar 40, and when can generic versions of Qvar 40 launch?

Qvar 40 is a drug marketed by Teva Branded Pharm and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and ninety-two patent family members in twenty-four countries.

The generic ingredient in QVAR 40 is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qvar 40

A generic version of QVAR 40 was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for QVAR 40

International Patents:	192
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QVAR 40

US Patents and Regulatory Information for QVAR 40

QVAR 40 is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y

International Patents for QVAR 40

When does loss-of-exclusivity occur for QVAR 40?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QVAR 40 around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2436414	Compteur de doses pour inhalateurs et inhalateur (Dose counter for inhalers and inhaler)
Denmark	2436414
Japan	6273242
Hungary	E026789

QVAR 40 Market Analysis and Financial Projection

Last updated: April 25, 2026

QVAR 40 fundamentals and investment scenario

QVAR 40 is an inhaled corticosteroid (ICS) pressurized metered-dose inhaler (pMDI) containing beclomethasone dipropionate (BDP). The product’s investment fundamentals are driven by (1) chronic use for asthma control, (2) inhaled-steroid substitution risk and payer formulary dynamics, (3) competitive positioning versus other ICS and combination inhalers, and (4) the duration and enforceability of product-level IP and regulatory exclusivities that protect QVAR formulations.

Business implication: QVAR is a “volume and access” asset. Without durable formulation-level protection and strong payer entrenchment, it faces margin compression from authorized generics and therapeutic substitution. The investment case is strongest when (a) the brand has durable formulary placement, (b) there is limited generic penetration for the specific dosage form and device, and (c) patient-through-device switching is constrained by clinical practice and device familiarity.

---

What is QVAR 40 and what does it sell as?

What is the drug and dosage form?

• Brand: QVAR 40
• Active ingredient: beclomethasone dipropionate (BDP)
• Formulation: pMDI (pressurized metered-dose inhaler)
• Strength: 40 micrograms (mcg) per actuation

Commercial meaning: QVAR 40 targets asthma maintenance via local anti-inflammatory action. It competes on device usability, dose reliability, and patient tolerance.

What is the intended use?

• Indication: asthma control (maintenance therapy)

Commercial meaning: Unlike acute therapies, QVAR depends on persistent adherence and stable refill cycles.

---

How do sales dynamics work for QVAR 40?

Is demand steady or cyclical?

Demand is structurally recurring. Asthma maintenance is a long-term category with periodic step-ups and step-downs based on control. The main “volatility valves” are:

• seasonal effects on exacerbations (affecting overall category demand and intensification)
• payer formulary revisions (switching between ICS brands and authorized generics)
• guideline-driven preferences among ICS molecules and delivery devices

What drives patient retention?

QVAR retention depends on:

• device familiarity: pMDI usage patterns differ from dry powder inhalers (DPIs)
• tolerability and symptom control: perceived efficacy and rescue inhaler reduction
• insurance coverage: copay positioning and prior authorization outcomes

Where does margin risk come from?

• Generic erosion typically targets brand economics first, then increases pressure on net price.
• Therapeutic substitution can occur even with generic availability, if payers steer to other ICS or ICS/LABA regimens.

---

Competitive landscape: where does QVAR 40 sit?

Which therapeutic categories are QVAR’s direct substitutes?

QVAR’s practical competitor set includes:

• other ICS inhalers (different molecules, different devices)
• ICS/LABA combinations when clinicians step up therapy
• device-specific pathways: pMDI vs DPI switching

What is the key competitive variable?

For an ICS brand, the decisive variables usually compress into two measurable levers:

• Net price vs. lowest-cost equivalent on formulary
• Formulary tier placement and utilization management (step therapy, prior authorization)

Investment implication: QVAR’s upside is tied more to payer access and contract economics than to incremental clinical differentiation.

---

Regulatory and exclusivity structure: what can protect QVAR 40?

What protection matters for an inhaled product?

For inhaled therapies, value is protected by a mix of:

• composition-of-matter (active ingredient-level IP) if still in force (often expired for older molecules)
• formulation and device-specific patents
• regulatory exclusivities tied to specific applications and changes
• market exclusivity from the first approved version or later “branded” reformulations

Commercial meaning: If QVAR 40’s current product is not protected robustly against generic/authorized generic entry for the same dosage form and device, it becomes a low-growth, share-taking asset.

---

Investment scenario: base case, bull case, bear case

Base case (access holds, modest share pressure)

Assumption set:

• QVAR 40 maintains meaningful formulary presence.
• Generic competition exists but does not fully displace QVAR due to device preference and payer contract economics.
• Uptake is stable; growth comes from category demand and asthma prevalence rather than major share capture.

Expected financial profile:

• mid-single digit revenue growth at the category level, net price slowly compressing
• gross margin pressure from competition and channel mix
• stable operating leverage only if marketing and contracting costs stay controlled

Bull case (payers entrench QVAR; fewer effective switches)

Assumption set:

• stronger-than-expected net retention from contracts and patient-through-provider prescribing patterns
• limited effective substitution due to device familiarity, adherence, and formulary restrictions on alternative ICS
• any formulation/device IP blocks or delayed approvals reduce direct price pressure

Expected financial profile:

• revenue outperformance versus category
• improved net pricing and slower gross margin compression
• higher earnings quality if market access remains resilient

Bear case (rapid displacement by lower-cost alternatives or step-up combinations)

Assumption set:

• accelerated erosion from authorized generics or pricing to maintain formulary position
• formulary tightening pushes patients toward cheaper ICS or ICS/LABA combinations
• increased copay pressure or utilization management failures reduce persistence

Expected financial profile:

• revenue decline from share loss
• sharper gross margin compression
• higher restructuring or cost control needs to offset falling net sales

---

Fundamentals checklist for an investment thesis

What to verify before underwriting the deal?

1. Payer footprint
   • Whether QVAR 40 is on preferred tiers for commercial and government plans
2. Switch rates
   • Evidence of real-world persistence after formulary changes
3. Price vs. equivalents
   • Net price trend relative to the lowest-cost ICS alternatives in the same tier
4. Generic/authorized generic status
   • Competitive set for the exact dosage form (pMDI) and strength (40 mcg)
5. IP and regulatory blocking
   • Whether active patents block substitution for the specific formulation/device and whether exclusivity still constrains generic approvals

---

Key risks and what they mean in practice

1) Generic and authorized generic competition

Risk: Even with brand loyalty, authorized generics can compress net pricing quickly.
Investment impact: Higher discount rates needed; downside protection depends on contract economics and device/prescriber lock-in.

2) Therapeutic substitution into step-up therapy

Risk: Asthma patients step up from ICS monotherapy to ICS/LABA combinations as control worsens.
Investment impact: QVAR can lose patients not only to competing ICS, but to combination therapy.

3) Formulary and PBM utilization management

Risk: Step therapy and prior authorization restrict access and reduce persistence.
Investment impact: Forecast sensitivity increases around PBM contract cycles.

4) Device preference and switching friction

Risk: If patients are switched from QVAR’s pMDI device to DPI or another pMDI, adherence can drop.
Investment impact: While switching friction can defend QVAR, it also creates churn risk if payers force changes.

---

Operational and diligence priorities for investors

Contracting signals that correlate with durability

• Multi-year formulary commitments
• Existence of preferred status for multiple disease severity groups
• Rebate structures that sustain net pricing

Commercial diligence signals

• Refill and persistence metrics by plan type
• Prescriber retention and share within targeted asthma clinics
• Time-on-treatment trend after step therapy initiation

Regulatory diligence signals

• Whether any product-specific IP continues to constrain direct copycat approvals
• Whether the market has effective one-to-one substitution with the same device and dose

---

Key Takeaways

• QVAR 40 is a chronic-use ICS pMDI. Its investment profile is dominated by payer access, net price trend, and persistence rather than short-cycle growth.
• The bull case requires payer entrenchment and limited effective substitution, supported by device and prescribing inertia.
• The bear case is driven by faster generic or authorized generic erosion and step-up migration into ICS/LABA combinations.
• Underwriting should focus on formulary tier durability, contract economics, and persistence after utilization management changes.

---

FAQs

1. Is QVAR 40 growth more dependent on new prescriptions or refill persistence?
   Refill persistence dominates. QVAR is maintenance therapy, so persistence and adherence drive sustained revenue.

2. What poses the biggest margin compression risk for QVAR 40?
   Price erosion from generics or authorized generics, combined with payer-driven net price pressure.

3. Does QVAR compete only with other inhaled corticosteroids?
   No. It also competes with step-up regimens that use combination inhalers when control worsens.

4. How does device type affect QVAR 40 investment durability?
   Device familiarity can reduce switching, but payer-driven forced switching can also harm persistence.

5. What diligence indicator best predicts whether QVAR holds share during formulary changes?
   Persistence and refill rates post-switch in the same formulary cohorts, plus net price retention versus the lowest-cost equivalents in the tier.

---

References

[1] FDA. “QVAR (beclomethasone dipropionate) Inhalation Aerosol” prescribing information. U.S. Food and Drug Administration.
[2] FDA. Drug Approval Reports and labeling for beclomethasone dipropionate inhalation aerosol products (QVAR-related approvals and regulatory history). U.S. Food and Drug Administration.
[3] GlobalData/IMS-style public market research (category and payer dynamics for asthma inhalers). Public market and reimbursement analyses.